Terms: = Leukemia AND FOXO3, FKHRL1, 2309, ENSG00000118689, MGC31925, MGC12739, FOXO2, FOXO3A, O43524, AF6q21, FKHRL1P2, DKFZp781A0677 AND Prognosis
21 results:
1. Prognostic value and therapeutic targeting of XPO1 in chronic lymphocytic leukemia.
Xu Z; Pan B; Miao Y; Li Y; Qin S; Liang J; Kong Y; Zhang X; Tang J; Xia Y; Zhu H; Wang L; Li J; Wu J; Xu W
Clin Exp Med; 2023 Oct; 23(6):2651-2662. PubMed ID: 36738306
[TBL] [Abstract] [Full Text] [Related]
2. U2AF1 mutation promotes tumorigenicity through facilitating autophagy flux mediated by foxo3a activation in myelodysplastic syndromes.
Zhu Y; Song D; Guo J; Jin J; Tao Y; Zhang Z; Xu F; He Q; Li X; Chang C; Wu L
Cell Death Dis; 2021 Jun; 12(7):655. PubMed ID: 34183647
[TBL] [Abstract] [Full Text] [Related]
3. FLT3 inhibition upregulates HDAC8 via FOXO to inactivate p53 and promote maintenance of FLT3-ITD+ acute myeloid leukemia.
Long J; Jia MY; Fang WY; Chen XJ; Mu LL; Wang ZY; Shen Y; Xiang RF; Wang LN; Wang L; Jiang CH; Jiang JL; Zhang WJ; Sun YD; Chang L; Gao WH; Wang Y; Li JM; Hong DL; Liang AB; Hu J
Blood; 2020 Apr; 135(17):1472-1483. PubMed ID: 32315388
[TBL] [Abstract] [Full Text] [Related]
4. Circ-foxo3 is positively associated with the foxo3 gene and leads to better prognosis of acute myeloid leukemia patients.
Zhou J; Zhou LY; Tang X; Zhang J; Zhai LL; Yi YY; Yi J; Lin J; Qian J; Deng ZQ
BMC Cancer; 2019 Sep; 19(1):930. PubMed ID: 31533653
[TBL] [Abstract] [Full Text] [Related]
5. Expression of the PTEN/foxo3a/PLZF signalling pathway in pancreatic cancer and its significance in tumourigenesis and progression.
Zhang Q; Li X; Li Y; Chen S; Shen X; Dong X; Song Y; Zhang X; Huang K
Invest New Drugs; 2020 Apr; 38(2):321-328. PubMed ID: 31087222
[TBL] [Abstract] [Full Text] [Related]
6. Promyelocytic leukemia protein (PML) controls breast cancer cell proliferation by modulating Forkhead transcription factors.
Sachini N; Arampatzi P; Klonizakis A; Nikolaou C; Makatounakis T; Lam EW; Kretsovali A; Papamatheakis J
Mol Oncol; 2019 Jun; 13(6):1369-1387. PubMed ID: 30927552
[TBL] [Abstract] [Full Text] [Related]
7. Akt2 mediates glucocorticoid resistance in lymphoid malignancies through foxo3a/Bim axis and serves as a direct target for resistance reversal.
Xie M; Yang A; Ma J; Wu M; Xu H; Wu K; Jin Y; Xie Y
Cell Death Dis; 2019 Jan; 9(10):1013. PubMed ID: 30598523
[TBL] [Abstract] [Full Text] [Related]
8. VEGFC Antibody Therapy Drives Differentiation of AML.
Kampen KR; Scherpen FJG; Mahmud H; Ter Elst A; Mulder AB; Guryev V; Verhagen HJMP; De Keersmaecker K; Smit L; Kornblau SM; De Bont ESJM
Cancer Res; 2018 Oct; 78(20):5940-5948. PubMed ID: 30185550
[TBL] [Abstract] [Full Text] [Related]
9. MicroRNA-155-5p Overexpression in Peripheral Blood Mononuclear Cells of Chronic Lymphocytic leukemia Patients Is a Novel, Independent Molecular Biomarker of Poor prognosis.
Papageorgiou SG; Kontos CK; Diamantopoulos MA; Bouchla A; Glezou E; Bazani E; Pappa V; Scorilas A
Dis Markers; 2017; 2017():2046545. PubMed ID: 29463948
[TBL] [Abstract] [Full Text] [Related]
10. The interplay of CD150 and CD180 receptor pathways contribute to the pathobiology of chronic lymphocytic leukemia B cells by selective inhibition of Akt and MAPK signaling.
Gordiienko I; Shlapatska L; Kholodniuk V; Sklyarenko L; Gluzman DF; Clark EA; Sidorenko SP
PLoS One; 2017; 12(10):e0185940. PubMed ID: 28982149
[TBL] [Abstract] [Full Text] [Related]
11. Overexpression of foxo3a is associated with glioblastoma progression and predicts poor patient prognosis.
Qian Z; Ren L; Wu D; Yang X; Zhou Z; Nie Q; Jiang G; Xue S; Weng W; Qiu Y; Lin Y
Int J Cancer; 2017 Jun; 140(12):2792-2804. PubMed ID: 28295288
[TBL] [Abstract] [Full Text] [Related]
12. Identification of FOXM1 as a therapeutic target in B-cell lineage acute lymphoblastic leukaemia.
Buchner M; Park E; Geng H; Klemm L; Flach J; Passegué E; Schjerven H; Melnick A; Paietta E; Kopanja D; Raychaudhuri P; Müschen M
Nat Commun; 2015 Mar; 6():6471. PubMed ID: 25753524
[TBL] [Abstract] [Full Text] [Related]
13. Decitabine priming enhances the antileukemic effects of exportin 1 (XPO1) selective inhibitor selinexor in acute myeloid leukemia.
Ranganathan P; Yu X; Santhanam R; Hofstetter J; Walker A; Walsh K; Bhatnagar B; Klisovic R; Vasu S; Phelps MA; Devine S; Shacham S; Kauffman M; Marcucci G; Blum W; Garzon R
Blood; 2015 Apr; 125(17):2689-92. PubMed ID: 25716206
[TBL] [Abstract] [Full Text] [Related]
14. Recurrent mutations refine prognosis in chronic lymphocytic leukemia.
Baliakas P; Hadzidimitriou A; Sutton LA; Rossi D; Minga E; Villamor N; Larrayoz M; Kminkova J; Agathangelidis A; Davis Z; Tausch E; Stalika E; Kantorova B; Mansouri L; Scarfò L; Cortese D; Navrkalova V; Rose-Zerilli MJ; Smedby KE; Juliusson G; Anagnostopoulos A; Makris AM; Navarro A; Delgado J; Oscier D; Belessi C; Stilgenbauer S; Ghia P; Pospisilova S; Gaidano G; Campo E; Strefford JC; Stamatopoulos K; Rosenquist R;
Leukemia; 2015 Feb; 29(2):329-36. PubMed ID: 24943832
[TBL] [Abstract] [Full Text] [Related]
15. [Expression of foxo3a in patients with acute myeloid leukemia and its clinical significance].
Zhao JN; Lu QY; Niu XQ; Zhang P; Wang Z; Lin JZ; Zhuang YH; Lu JY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Aug; 21(4):847-50. PubMed ID: 23998572
[TBL] [Abstract] [Full Text] [Related]
16. Cytotoxic activity of the novel Akt inhibitor, MK-2206, in T-cell acute lymphoblastic leukemia.
Simioni C; Neri LM; Tabellini G; Ricci F; Bressanin D; Chiarini F; Evangelisti C; Cani A; Tazzari PL; Melchionda F; Pagliaro P; Pession A; McCubrey JA; Capitani S; Martelli AM
Leukemia; 2012 Nov; 26(11):2336-42. PubMed ID: 22614243
[TBL] [Abstract] [Full Text] [Related]
17. Aberrant microRNA-182 expression is associated with glucocorticoid resistance in lymphoblastic malignancies.
Yang A; Ma J; Wu M; Qin W; Zhao B; Shi Y; Jin Y; Xie Y
Leuk Lymphoma; 2012 Dec; 53(12):2465-73. PubMed ID: 22582938
[TBL] [Abstract] [Full Text] [Related]
18. Hypomethylating agents reactivate foxo3A in acute myeloid leukemia.
Thépot S; Lainey E; Cluzeau T; Sébert M; Leroy C; Adès L; Tailler M; Galluzzi L; Baran-Marszak F; Roudot H; Eclache V; Gardin C; de Botton S; Auberger P; Fenaux P; Kroemer G; Boehrer S
Cell Cycle; 2011 Jul; 10(14):2323-30. PubMed ID: 21654193
[TBL] [Abstract] [Full Text] [Related]
19. Repression of BMI1 in normal and leukemic human CD34(+) cells impairs self-renewal and induces apoptosis.
Rizo A; Olthof S; Han L; Vellenga E; de Haan G; Schuringa JJ
Blood; 2009 Aug; 114(8):1498-505. PubMed ID: 19556423
[TBL] [Abstract] [Full Text] [Related]
20. High foxo3a expression is associated with a poorer prognosis in AML with normal cytogenetics.
Santamaría CM; Chillón MC; García-Sanz R; Pérez C; Caballero MD; Ramos F; de Coca AG; Alonso JM; Giraldo P; Bernal T; Queizán JA; Rodriguez JN; Fernández-Abellán P; Bárez A; Peñarrubia MJ; Vidriales MB; Balanzategui A; Sarasquete ME; Alcoceba M; Díaz-Mediavilla J; San Miguel JF; Gonzalez M
Leuk Res; 2009 Dec; 33(12):1706-9. PubMed ID: 19457552
[TBL] [Abstract] [Full Text] [Related]
[Next]
